APA (7th ed.) Citation

A, R., E, L., S, L., N, P., S, S., N, M., . . . G, F. (2026). Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia. Asia-Pacific journal of clinical oncology, 22(3), 381. https://doi.org/10.1111/ajco.70069

Chicago Style (17th ed.) Citation

A, Redfern, Lim E, Lakhani S, Pathmanathan N, Selva-Nayagam S, McCarthy N, Yeo B, Dessauvagie B, and Farshid G. "Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia." Asia-Pacific Journal of Clinical Oncology 22, no. 3 (2026): 381. https://doi.org/10.1111/ajco.70069.

MLA (9th ed.) Citation

A, Redfern, et al. "Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia." Asia-Pacific Journal of Clinical Oncology, vol. 22, no. 3, 2026, p. 381, https://doi.org/10.1111/ajco.70069.